Case Report: Deutetrabenazine as an Adjunctive Treatment for Stuttering
Childhood-Onset Fluency Disorder (Stuttering) is a neurodevelopmental disorder in which disturbances occur in the normal fluency and time patterning of speech. While the dopamine system has been well-described in its neurophysiology, there currently is no FDA-approved treatment for stuttering. Secon...
Saved in:
| Published in: | Frontiers in psychiatry Vol. 12 |
|---|---|
| Main Authors: | , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Frontiers Media S.A
25-10-2021
|
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Childhood-Onset Fluency Disorder (Stuttering) is a neurodevelopmental disorder in which disturbances occur in the normal fluency and time patterning of speech. While the dopamine system has been well-described in its neurophysiology, there currently is no FDA-approved treatment for stuttering. Second-generation antipsychotics, which have been effective in the treatment of schizophrenia and bipolar disorder, act as dopamine D-2 receptor antagonists at the postsynaptic neuron and have been shown to reduce the symptoms of stuttering. However, the D-2 receptor antagonist and partial agonist agents carry the potential for metabolic side effects and can potentially lead to movement disorders. Deutetrabenazine, a VMAT-2 inhibitor indicated to treat hyperkinetic movement disorders, is a potential candidate in the treatment of stuttering, based on its mechanism of action in decreasing dopamine activity while not carrying the risk of metabolic adverse events. |
|---|---|
| Bibliography: | Edited by: Mirko Manchia, University of Cagliari, Italy Reviewed by: Giorgio Pigato, University Hospital of Padua, Italy; Pasquale Paribello, University of Cagliari, Italy This article was submitted to Psychopharmacology, a section of the journal Frontiers in Psychiatry |
| ISSN: | 1664-0640 1664-0640 |
| DOI: | 10.3389/fpsyt.2021.683368 |